• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.

作者信息

Barzegar Mahdi, Mirmosayyeb Omid, Nehzat Nasim, Sarrafi Reza, Khorvash Farzin, Maghzi Amir-Hadi, Shaygannejad Vahid

机构信息

From the Department of Neurology (M.B., O.M., R.S., V.S.), School of Medicine, Isfahan University of Medical Sciences; Isfahan Neurosciences Research Center (M.B., O.M., N.N., V.S.), Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center (F.K.), Isfahan University of Medical Sciences, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

出版信息

Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4). doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.

DOI:10.1212/NXI.0000000000000753
PMID:32371550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7217655/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a11/7217655/bf0f1bd313de/NEURIMMINFL2020029033f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a11/7217655/bf0f1bd313de/NEURIMMINFL2020029033f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a11/7217655/bf0f1bd313de/NEURIMMINFL2020029033f1.jpg

相似文献

1
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.一名接受芬戈莫德治疗的多发性硬化症患者感染了新冠病毒。
Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4). doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.
2
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.两名接受芬戈莫德治疗的多发性硬化症患者出现无症状的严重急性呼吸综合征冠状病毒2感染。
Mult Scler Relat Disord. 2020 Oct;45:102414. doi: 10.1016/j.msard.2020.102414. Epub 2020 Jul 19.
3
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.多发性硬化症（MS）药物可能成为 COVID-19 患者中急性呼吸窘迫综合征（ARDS）的一种治疗方法。
Mult Scler Relat Disord. 2020 Oct;45:102437. doi: 10.1016/j.msard.2020.102437. Epub 2020 Jul 31.
4
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.免疫抑制多发性硬化症患者从 SARS-CoV-2 感染中康复后的免疫特征。
J Neuroimmunol. 2020 Aug 15;345:577282. doi: 10.1016/j.jneuroim.2020.577282. Epub 2020 May 29.
5
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.多发性硬化症患者在接受芬戈莫德治疗后感染严重 COVID-19。
Mult Scler Relat Disord. 2020 Jul;42:102180. doi: 10.1016/j.msard.2020.102180. Epub 2020 May 6.
6
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
7
COVID-19 will change MS care forever - No.新冠疫情将永远改变多发性硬化症的护理——不。
Mult Scler. 2020 Sep;26(10):1149-1151. doi: 10.1177/1352458520929971. Epub 2020 Jun 22.
8
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.冠状病毒病（COVID-19）大流行对多发性硬化症护理的影响。
Clin Neurol Neurosurg. 2020 Oct;197:106203. doi: 10.1016/j.clineuro.2020.106203. Epub 2020 Sep 2.
9
COVID-19 in teriflunomide-treated patients with multiple sclerosis.新冠肺炎在多发性硬化症接受特立氟胺治疗的患者中。
J Neurol. 2020 Oct;267(10):2790-2796. doi: 10.1007/s00415-020-09944-8. Epub 2020 Jun 3.
10
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.在新冠疫情期间治疗多发性硬化症患者：评估专家建议。
Mult Scler Relat Disord. 2020 Aug;43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.

引用本文的文献

1
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.一项多中心纵向研究分析了 COVID-19 大流行期间多发性硬化症的疾病修正治疗处方模式。
J Neurol. 2024 Sep;271(9):5813-5824. doi: 10.1007/s00415-024-12518-7. Epub 2024 Jun 27.
2
Implementing coronavirus disease 2019 scale-up registry protocol in national multiple sclerosis registry system of Iran.在伊朗国家多发性硬化症登记系统中实施2019冠状病毒病扩大登记方案。
Curr J Neurol. 2021 Oct 7;20(4):241-245. doi: 10.18502/cjn.v20i4.8351.
3
The effect of Fingolimod on patients with moderate to severe COVID-19.

本文引用的文献

1
The COVID-19 pandemic and the use of MS disease-modifying therapies.新冠疫情与多发性硬化症疾病修正疗法的使用
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
2
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
3
Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection.胸部计算机断层扫描在 2019 年冠状病毒病（COVID-19）中的表现：与感染持续时间的关系。
芬戈莫德对中重度 COVID-19 患者的影响。
Pharmacol Res Perspect. 2023 Feb;11(1):e01039. doi: 10.1002/prp2.1039.
4
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.COVID-19 患者使用鞘氨醇-1-磷酸受体调节剂的理由：科学证据概述。
J Interferon Cytokine Res. 2023 Jun;43(6):246-256. doi: 10.1089/jir.2022.0078. Epub 2022 Nov 29.
5
Monkeypox in Multiple Sclerosis patients: Should we be alert?多发性硬化症患者中的猴痘：我们应该警惕吗？
Mult Scler Relat Disord. 2022 Nov;67:104228. doi: 10.1016/j.msard.2022.104228. Epub 2022 Oct 8.
6
COVID-19 and the risk of CNS demyelinating diseases: A systematic review.2019冠状病毒病与中枢神经系统脱髓鞘疾病风险：一项系统评价
Front Neurol. 2022 Sep 20;13:970383. doi: 10.3389/fneur.2022.970383. eCollection 2022.
7
An Overview of Neurological and Psychiatric Complications During Post-COVID Period: A Narrative Review.新冠疫情后时期神经和精神并发症概述：一项叙述性综述
J Inflamm Res. 2022 Jul 26;15:4199-4215. doi: 10.2147/JIR.S375494. eCollection 2022.
8
Inflammatory activation and immune cell infiltration are main biological characteristics of SARS-CoV-2 infected myocardium.炎症激活和免疫细胞浸润是 SARS-CoV-2 感染心肌的主要生物学特征。
Bioengineered. 2022 Feb;13(2):2486-2497. doi: 10.1080/21655979.2021.2014621.
9
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.治疗 COVID-19 的小分子临床试验的种族差异：最新全面综述。
Drug Dev Res. 2022 Feb;83(1):16-54. doi: 10.1002/ddr.21895. Epub 2021 Nov 11.
10
Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage.冠状病毒病时代肺部病理学中的鞘脂：鞘脂参与肺损伤发病机制的综述
Front Physiol. 2021 Oct 8;12:760638. doi: 10.3389/fphys.2021.760638. eCollection 2021.
Radiology. 2020 Jun;295(3):200463. doi: 10.1148/radiol.2020200463. Epub 2020 Feb 20.
4
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.芬戈莫德反弹：临床经验与管理考量综述
Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.
5
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.多发性硬化症患者接受芬戈莫德、那他珠单抗、利妥昔单抗和注射治疗的感染风险。
JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.
6
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.停用芬戈莫德后，孕期多发性硬化症出现显著反弹。
Neurol Neuroimmunol Neuroinflamm. 2017 Jul 27;4(5):e377. doi: 10.1212/NXI.0000000000000377. eCollection 2017 Sep.
7
Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation.感染作为多发性硬化症病情加重的环境触发因素。
Front Immunol. 2015 Oct 19;6:520. doi: 10.3389/fimmu.2015.00520. eCollection 2015.